Get started
Author

Naomi van Hest

Observed names: N van Hest, N. van Hest, Naomi Van Hest, van Hest N, van Hest, Naomi
ORCID: 0009-0001-2282-8584
Observed ORCID: 0009-0001-2282-8584
OpenAlex ID: A5041900444
Causes of death among people who used illicit opioids in England, 2001–18: a matched cohort study
2021 · Dan Lewer, Thomas D Brothers, et al. · The Lancet Public Health · 62
PDF
Healthcare resource use and associated costs for patients with an ileostomy experiencing peristomal skin complications
2023 · N. Rolls, L. de Fries Jensen, et al. · International Wound Journal · 27
Health‐care resource use among patients who use illicit opioids in England, 2010–20: A descriptive matched cohort study
2023 · Naomi van Hest, Thomas D. Brothers, et al. · Addiction · 8
PDF
Pdg85 Trust the Experts? Acceptance of Expert Elicitation in the National Institute for Health and Care Excellence (nice) Single Technology Appraisal (sta) Process
2019 · N. van Hest, E. Upton, et al. · Value in Health · 5
PDF
Cost-Effectiveness of a Digital Leakage Notification System (Heylo™) for People with Ileostomies or Colostomies in the United Kingdom
2025 · Esben Bo Boisen, Matthew Cawson, et al. · PharmacoEconomics · 3
PDF
Cost-Effectiveness of Tirzepatide Versus Liraglutide, Both Adjunct to Diet and Exercise, for Patients with Obesity or Overweight: A UK Perspective
2025 · Matthew Capehorn, Erin Johansson, et al. · Advances in Therapy · 2
PDF
EE117 Cost-Effectiveness of Tirzepatide Versus Semaglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective
2024 · M Capehorn, E Johansson, et al. · Value in Health · 2
Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
2023 · Naomi van Hest, Peter Morten, et al. · Journal of health economics and outcomes research · 2
MSR63 When Does a Treatment Effect Really Stop? Exploration of Different Methods for Modelling Treatment Waning
2022 · J Micallef, HE Harrington, et al. · Value in Health · 2
PDF
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study
2026 · Lieven Annemans, Erin Johansson, et al. · Journal of Medical Economics · 1
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
2026 · Erin Johansson, John P. H. Wilding, et al. · Journal of Medical Economics · 1
PDF
EE354 An Exploratory Cost-Effectiveness Analysis of Cancer Vaccines in Combination With Current Immune Checkpoint Inhibitors Vs Immune Checkpoint Inhibitor Monotherapy: A Case Study for V940 in High-Risk Stage 3 Melanoma in the US
2024 · A Mclean, N van Hest · Value in Health · 1
PDF
EE287 Cost-Effectiveness of Tirzepatide As an Adjunct to a Reduced-Calorie Diet and Increased Physical Activity Versus Diet and Exercise Alone in Patients With Obesity or Overweight From a UK Perspective
2024 · M Capehorn, LM Evans, et al. · Value in Health · 1
PDF
EE789 Cost-Effectiveness of Tirzepatide Versus Liraglutide (Both Adjunct to a Reduced-Calorie Diet and Increased Physical Activity) in Patients With Obesity or Overweight From a UK Perspective
2024 · M Capehorn, E Johansson, et al. · Value in Health · 1
PDF
EE198 A Targeted Literature Review of Treatment Sequencing Approaches in Economic Analyses in Relapsing Multiple Sclerosis
2023 · T. Kloska, S. Wright, et al. · Value in Health · 1
PRO140 Health-Related Quality of Life Associated with Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma Patients: Determination of Utility Values from a UK-Based Clinician Questionnaire
2020 · J. Scarisbrick, F. Schmidt, et al. · Value in Health · 1
Pcn4 Accuracy of Life Year Gain Predictions for Nivolumab Monotherapy in the Long Term: an Analysis Across Four Indications
2020 · A. Porteous, N. van Hest, et al. · Value in Health · 1
Prm109 - Exploring the Use and Acceptance of Alternative Survival Modelling Approaches for Immuno-oncology Therapies in Uk Technology Assessments
2018 · A Porteous, N. van Hest, et al. · Value in Health · 1
Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission – a UK case study
2026 · Annemans, Lieven, Johansson, Erin, et al. · Figshare
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
2026 · Johansson, Erin, Wilding, John P. H., et al. · Figshare
EE342 Does Modeling Adherence Matter? Insights From Prior NICE Appraisals
2025 · Thomas P. Kloska, Jessica Amis, et al. · Value in Health
MSR101 Excel Front-End, R Back-End: A Gateway to Faster Individual Patient Simulations and Probabilistic Sensitivity Analyses in Cost-Effectiveness Models for HTA
2025 · Laura J. Clark, Alex Mclean, et al. · Value in Health
EE135 Comparative Analysis of Pan-European Severity Assessment Methods and Their Uncertainty in Cost-Effectiveness Analysis
2025 · Alex Mclean, Naomi van Hest · Value in Health
P26 Comparison of Cost-Effectiveness Model Outcomes Using Two Individual-Level Simulation Models in Obesity
2024 · L Ni, M Harris, et al. · Value in Health
PDF
MSR53 Flexsurv Methods to Estimate Cure: An Exploration of Methods for Modelling Cure
2023 · S. Venkada Subramaniyan, L. Clark, et al. · Value in Health
Works count: 34
Citation count: 122
H-index: 4
I10-index: 2
Year
Topic
Type